175 related articles for article (PubMed ID: 33128591)
1. Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.
Quintilhano DL; Miksza DR; de Souza Galia WB; Ramalho MORC; Lucena CF; Valle MMR; Graciano MFR; de Souza HM; Bertolini GL
Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):697-705. PubMed ID: 33128591
[TBL] [Abstract][Full Text] [Related]
2. Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
Quintilhano DL; Miksza DR; Biazi GR; Frasson-Uemura IG; Graciano MFR; Mazzuco TL; Carpinelli ÂR; de Souza HM; Bertolini GL
Cell Biochem Funct; 2021 Mar; 39(2):335-343. PubMed ID: 32911572
[TBL] [Abstract][Full Text] [Related]
3. Akt activation by insulin treatment attenuates cachexia in Walker-256 tumor-bearing rats.
de Fatima Silva F; de Morais H; Ortiz Silva M; da Silva FG; Vianna Croffi R; Serrano-Nascimento C; Rodrigues Graciano MF; Rafael Carpinelli A; Barbosa Bazotte R; de Souza HM
J Cell Biochem; 2020 Nov; 121(11):4558-4568. PubMed ID: 32056265
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin on insulin resistance and metabolic disorders in tumor-bearing rats with advanced cachexia.
de Fatima Silva F; Ortiz-Silva M; Galia WBS; Cassolla P; da Silva FG; Graciano MFR; Carpinelli AR; de Souza HM
Can J Physiol Pharmacol; 2018 May; 96(5):498-505. PubMed ID: 29304290
[TBL] [Abstract][Full Text] [Related]
5. Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity.
Miksza DR; Biazi GR; Frasson IG; de Souza Galia WB; Ferraz LS; Diaz BF; Kurauti MA; Marmentini C; Mareze-Costa CE; Peres SB; Cassolla P; Bertolini GL; Bazotte RB; de Souza HM
Pharmacol Rep; 2023 Dec; 75(6):1571-1587. PubMed ID: 37804392
[TBL] [Abstract][Full Text] [Related]
6. Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.
Charpentier J; Waget A; Klopp P; Magnan C; Cruciani-Guglielmacci C; Lee SJ; Burcelin R; Grasset E
Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G671-G684. PubMed ID: 30070580
[TBL] [Abstract][Full Text] [Related]
7. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
[TBL] [Abstract][Full Text] [Related]
8. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Bolli GB; Owens DR
Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretion in Walker 256 tumor cachexia.
Fernandes LC; Machado UF; Nogueira CR; Carpinelli AR; Curi R
Am J Physiol; 1990 Jun; 258(6 Pt 1):E1033-6. PubMed ID: 2193528
[TBL] [Abstract][Full Text] [Related]
10. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
Becker RH; Stechl J; Msihid J; Kapitza C
Diabetes Obes Metab; 2014 Sep; 16(9):793-800. PubMed ID: 24521245
[TBL] [Abstract][Full Text] [Related]
11. Aerobic Exercise Training Attenuates Tumor Growth and Reduces Insulin Secretion in Walker 256 Tumor-Bearing Rats.
Moreira VM; da Silva Franco CC; Prates KV; Gomes RM; de Moraes AMP; Ribeiro TA; Martins IP; Previate C; Pavanello A; Matiusso CCI; Almeida DL; Francisco FA; Malta A; Tófolo LP; da Silva Silveira S; Saavedra LPJ; Machado K; da Silva PHO; Fabrício GS; Palma-Rigo K; de Souza HM; de Fátima Silva F; Biazi GR; Pereira TS; Vieira E; Miranda RA; de Oliveira JC; da Costa Lima LD; Rinaldi W; Ravanelli MI; de Freitas Mathias PC
Front Physiol; 2018; 9():465. PubMed ID: 29867528
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Werner U; Haschke G; Herling AW; Kramer W
Regul Pept; 2010 Sep; 164(2-3):58-64. PubMed ID: 20570597
[TBL] [Abstract][Full Text] [Related]
13. Insulin, not glutamine dipeptide, reduces lipases expression and prevents fat wasting and weight loss in Walker 256 tumor-bearing rats.
de Morais H; de Fatima Silva F; da Silva FG; Silva MO; Graciano MFR; Martins MIL; Carpinelli ÂR; Mazucco TL; Bazotte RB; de Souza HM
Eur J Pharmacol; 2017 Jul; 806():67-74. PubMed ID: 28390870
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone improves insulin sensitivity and reduces weight loss in Walker-256 tumor-bearing rats.
de Fatima Silva F; Ortiz-Silva M; de Souza Galia WB; Cassolla P; Graciano MF; Zaia CT; Zaia D; Carpinelli ÂR; da Silva FG; de Souza HM
Life Sci; 2017 Feb; 171():68-74. PubMed ID: 28034669
[TBL] [Abstract][Full Text] [Related]
15. Peripheral insulin resistance is early, progressive, and correlated with cachexia in Walker-256 tumor-bearing rats.
de Morais H; Bôas SKFV; de Souza CO; Miksza DR; Moreira CCL; Kurauti MA; Silva FF; Cassolla P; Silva FGD; Limiere LC; Grassiolli S; Bazotte RB; de Souza HM
Cell Biochem Funct; 2023 Dec; 41(8):1252-1262. PubMed ID: 37787620
[TBL] [Abstract][Full Text] [Related]
16. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
[TBL] [Abstract][Full Text] [Related]
17. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J; Persson M; Ahrén B
Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
[TBL] [Abstract][Full Text] [Related]
18. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
McCarty D; Coleman M; Boland CL
Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
[TBL] [Abstract][Full Text] [Related]
19. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
20. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
